ArticleTranslational cancer research2025
Real-time prognosis prediction with conditional survival analysis for skull base chordoma based on SEER.
Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Skull base chordoma (SBC) is a rare, locally aggressive malignant bone tumor with a poor prognosis due to its location and recurrence. Despite advances in surgery and radiotherapy (RT), long-term survival remains uncertain. Traditional survival analyses are limited by their static nature, failing to capture the dynamic changes in survival probabilities over time. To address this, we applied conditional survival (CS) analysis for more precise evaluation of evolving survival rates in SBC patients. Methods: Data of 717 SBC patients [2000-2019] from SEER (Surveillance, Epidemiology, and End Results) database were obtained. Using CS analysis, we evaluated survival probabilities over time and developed the first SBC-specific CS-nomogram. Key clinicopathological factors were incorporated into the model via least absolute shrinkage and selection operator (LASSO) and multivariate Cox analysis. The nomogram was validated with training and validation cohorts. Calibration curves, C-index, time-dependent receiver operating characteristic (ROC) curves and decision curve analysis (DCA) were used to evaluate model performance. Results: CS analysis showed a steady overall survival (OS) improvement in SBC patients over time. The 10-year survival probability rose from 61% at diagnosis to 98% after 9 years. Eight clinicopathological factors, significant predictors of OS, were incorporated into the CS-nomogram. The model had robust predictive accuracy, with C-index values of 0.703 (training) and 0.731 (validation). Calibration curves and DCA indicated good agreement between predicted and actual outcomes with significant net clinical benefit. Conclusions: Combining CS analysis and a nomogram, we developed a new tool for dynamic, individualized survival predictions in SBC patients. The CS-nomogram can improve clinical decision-making and patient counseling, bringing hope and more precise prognostic evaluations for long-term survivors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.